Featured Research

from universities, journals, and other organizations

Beta-blockers may be associated with benefits in patients with lung disease

Date:
May 25, 2010
Source:
JAMA and Archives Journals
Summary:
Patients with chronic obstructive pulmonary disease may have fewer respiratory flare-ups and longer survival if they take beta-blocker medications, according to a new report.

Patients with chronic obstructive pulmonary disease (COPD) may have fewer respiratory flare-ups and longer survival if they take beta-blocker medications, according to a report in the May 24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

By the year 2020, COPD -- a diagnosis that includes emphysema and chronic bronchitis -- is expected to become the third leading cause of death in the Western world, according to background information in the article. Patients with the condition are also prone to develop and die from cardiovascular diseases. Medications known as beta-blockers, used to treat high blood pressure and heart rhythm disorders, are known to improve the survival of patients with cardiovascular disease. However, clinicians avoid use of beta-blockers in patients with COPD because of concerns about adverse effects on the lungs.

Frans H. Rutten, M.D., Ph.D., of University Medical Center Utrecht, the Netherlands, studied data from electronic medical records of 2,230 patients (average age 64.8) with COPD who visited 23 general medical practices between 1996 and 2006. Of these, 560 had COPD at the start of the study and 1,670 developed it during the study period; 665 used beta-blockers and 1,565 did not.

During an average of 7.2 years of follow-up, 686 patients (30.8 percent) died, including 27.2 percent of those who used a beta-blocker compared with 32.3 percent of those who did not use a beta-blocker. In addition, 1,055 patients (47.3 percent) had at least one exacerbation of COPD, including 42.7 percent of those who had used a beta blocker and 49.3 percent of those who did not use a beta-blocker.

Among the subgroup of 1,229 patients without overt cardiovascular disease, 520 (42.3 percent) experienced at least one exacerbation of COPD and 241 (19.6 percent) died. These outcomes were both less likely among the 239 patients (19.4 percent) who used beta-blockers.

"To our knowledge, this is the first observational study that shows that long-term treatment with beta-blockers may improve survival and reduce the risk of an exacerbation of COPD in the broad spectrum of patients with a diagnosis of COPD, including those who have COPD with but, importantly, also without overt cardiovascular comorbidities," the authors write.

"Whether beta-blockers can also cause beneficial pulmonary [lung] activity and therefore are truly 'cardiopulmonary' drugs remains to be proved," the authors write. Randomized controlled trials to assess the use of beta-blockers in patients with COPD are necessary, they conclude.

Editorial: Beta-Blockers May Provide New Hope for Patients With COPD

Although beta-blockers reduce deaths among patients with some cardiovascular conditions by 30 percent to 40 percent, their use "is frequently withheld in patients who have co-existing COPD because clinicians fear that beta-blockers will provoke bronchospasm and induce respiratory failure in these patients," write Don D. Sin, M.D., M.P.H., and S.F. Paul Man, M.D., of the University of British Columbia and the Providence Heart and Lung Institute, Vancouver, Canada, in an accompanying editorial.

"Not surprisingly, large epidemiological studies have shown that fewer than one-third of patients with COPD receive beta-blockers after an acute coronary event despite compelling data that they prolong life and improve health outcomes in such patients," they continue.

"The study by Rutten et al provocatively suggests that the use of beta-blockers, contrary to classic teaching, is not only safe but also can prolong survival and reduce exacerbations in COPD, providing new hope for patients with COPD," they conclude. "However, before we can fully accept this notion, a large, well-conducted, randomized controlled trial will be needed to confirm these findings. Until then, the data by Rutten and colleagues provides a rationale for the practicing clinicians to use beta-blockers cautiously in their patients with COPD who also have a co-existing cardiovascular condition for which a beta-blocker is required."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal References:

  1. Frans H. Rutten; Nicolaas P. A. Zuithoff; Eelko Hak; Diederick E. Grobbee; Arno W. Hoes. β-Blockers May Reduce Mortality and Risk of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease. Arch Intern Med., 2010;170(10):880-887. [link]
  2. Don D. Sin; S. F. Paul Man. A Curious Case of β-Blockers in Chronic Obstructive Pulmonary Disease. Arch Intern Med, 2010; 170 (10): 849-850 [link]

Cite This Page:

JAMA and Archives Journals. "Beta-blockers may be associated with benefits in patients with lung disease." ScienceDaily. ScienceDaily, 25 May 2010. <www.sciencedaily.com/releases/2010/05/100524161246.htm>.
JAMA and Archives Journals. (2010, May 25). Beta-blockers may be associated with benefits in patients with lung disease. ScienceDaily. Retrieved September 16, 2014 from www.sciencedaily.com/releases/2010/05/100524161246.htm
JAMA and Archives Journals. "Beta-blockers may be associated with benefits in patients with lung disease." ScienceDaily. www.sciencedaily.com/releases/2010/05/100524161246.htm (accessed September 16, 2014).

Share This



More Health & Medicine News

Tuesday, September 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

AFP (Sep. 16, 2014) Since the arrival of Ebola in Ivory Coast, Ivorians have been abandoning their pets, particularly monkeys, in the fear that they may transmit the virus. Duration: 00:47 Video provided by AFP
Powered by NewsLook.com
Study Links Male-Pattern Baldness To Prostate Cancer

Study Links Male-Pattern Baldness To Prostate Cancer

Newsy (Sep. 16, 2014) New findings suggest men with a certain type of baldness at age 45 are 39 percent more likely to develop aggressive prostate cancer. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins